Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.
Milena Braga-BasariaThomas G TravisonMary-Ellen TaplinAlexander P LinAlyssa B DufourDaniel HabtemariamPaul L NguyenAdam S KibelPraful RaviRichelle BearupHannah KackleyHussein KafelKieran ReidThomas StorerDonald C SimonsonMarie McDonnellShehzad BasariaPublished in: PloS one (2023)
Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It is also associated with loss of muscle mass and increased adiposity. This change in body composition is likely the inciting event in the development of insulin resistance, an independent risk factor for diabetes mellitus and cardiovascular disease. Although the occurrence of insulin resistance during ADT has been reported, it remains unclear whether this insulin resistance is primarily hepatic or muscular. Similarly, the mechanisms that lead to insulin resistance also remain unknown. The ADT & Metabolism Study was designed to address these knowledge gaps, as the elucidation of the predominant site of insulin resistance will allow prevention strategies and the use of targeted, tissue-specific insulin-sensitizing agents in patients undergoing ADT. This prospective, mechanistic, single-center, 24-week, observational cohort study will enroll treatment-naïve adult men with prostate cancer about to undergo surgical or medical ADT for at least 24 weeks (ADT group; n = 50) and a control group of men who had undergone radical prostatectomy and are in remission (non-ADT group, n = 25). The primary outcome is to determine the site of insulin resistance (skeletal muscle or liver) using frequent sampling oral glucose tolerance test at baseline and 12 and 24 weeks after commencement of ADT (ADT group) or after enrollment in the study (non-ADT group). Secondary outcomes will assess changes in hepatic and intramyocellular fat (using magnetic resonance spectroscopy), inflammatory markers, adipokines, free fatty acids, and changes in body composition (assessed using dual-energy x-ray absorptiometry) and their correlation with the development of insulin resistance. Exploratory outcomes will include changes in muscle performance, physical function, physical activity, vitality, and sexual drive.
Keyphrases
- insulin resistance
- prostate cancer
- body composition
- skeletal muscle
- radical prostatectomy
- adipose tissue
- high fat diet
- type diabetes
- metabolic syndrome
- polycystic ovary syndrome
- bone mineral density
- dual energy
- resistance training
- high fat diet induced
- glycemic control
- cardiovascular disease
- physical activity
- patients undergoing
- fatty acid
- study protocol
- healthcare
- squamous cell carcinoma
- computed tomography
- clinical trial
- middle aged
- locally advanced
- mental health
- rheumatoid arthritis
- coronary artery disease
- stem cells
- drug delivery
- bone marrow
- magnetic resonance imaging
- small cell lung cancer
- systemic lupus erythematosus
- combination therapy
- high resolution
- young adults
- magnetic resonance
- oxidative stress
- health insurance
- smoking cessation
- cardiovascular events